UroGen Pharma
Highly Engaged Employees
Manufacturing Ā· New Jersey, United States Ā· 201-500 Employees
View Company Info for Free
Overview
Headquarters
400 Alexander Park Fl 4, Princeton, New ...Phone Number
(646) 768-9780Website
www.urogen.comRevenue
$188.7 MillionStock Symbol
URGNIndustry
About UroGen Pharma
UroGen Pharma Org Chart
Is UroGen Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on UroGen Pharma recently announced quarterly report
Funding: Get notified immidiatlly once UroGen Pharma has new funding data
Website visits: Recent activity has been detected on your website
Click to see if UroGen Pharma had a recent Job posting/layoffs
Check if UroGen Pharma has recently received funding, and reach out quickly before it becomes old news!
Check out if UroGen Pharma is spiking on competitors!
UroGen Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when UroGen Pharma launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at UroGen Pharma
Recommended Actions
Find VP level buyers at UroGen Pharma
Find 3 more new buyers
Compare Similar Companies to UroGen Pharma
Compare insights from companies similar to UroGen Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
UroGen Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
UroGen Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about UroGen Pharma.
UroGen Pharma financials insights
Gather financial insights about UroGen Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Private Equity
$75M
Other Financing Round
$120M
UroGen Pharma Tech Stack
A closer look at the technologies used by UroGen Pharma
Most Recent Scoops
UroGen Pharma News & Media
IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies
IntraGel secures up to $7 million equity investment from UroGenĀ® to advance the Phase 2 clinical study of TumoCure, for the treatment of advanced head and neck cancer UroGen gains access to IntraGel's biodegradable sustained-release gel platform with broad potential across solid tumors,...UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC
UroGen files NDA for UGN-103 for treatment of LG-IR-NMIBCUroGen Pharma Ltd. (URGN) Q2 2026 Earnings Call Transcript
UroGen Pharma Ltd. (URGN) Q2 2026 Earnings Call August 5, 2026 10:00 AM EDTCompany ParticipantsVincent Perrone - Senior Director of Investor...UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
PRINCETON, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent developments.
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding UroGen Pharma
UroGen Pharma is a biopharmaceutical company focused on developing innovative therapeutic solutions for specialty cancers and urologic diseases. The company operates with a core mission to address unmet medical needs in areas where current treatment options remain limited, working to expand the arsenal of therapies available to patients facing comp... Read More